8-K: Beyond Air Reports 17% Revenue Increase and Secures Funding, Extending Cash Runway to June 2026

Beyond Air announced a 17% revenue increase compared to the previous quarter, secured $20.6 million in funding, and extended its cash runway through June 2026.

Summary

• Beyond Air reported a 17% increase in revenue for the quarter ended September 30, 2024, compared to the previous quarter.
• The company's customer base grew by over 60% during the quarter.
• Annualized contracted revenue reached $3.5 million as of October 1, 2024, with additional hospitals expected to contribute in the next quarter.
• A $20.6 million private placement was completed with healthcare-focused institutional funds and company insiders.
• The company retired $17.5 million in debt from Avenue Capital and entered into a $11.5 million loan agreement with an insider-led investor group.
• The company expects its strengthened balance sheet and cash conservation strategy to provide sufficient cash runway through June 2026.
• The company's cash burn for the quarter was $11.5 million, excluding financing and one-time items.
• As of September 30, 2024, the company had $28.4 million in cash, cash equivalents, and marketable securities, and $12.5 million in total debt.
• Pro forma cash was $18.5 million and pro forma outstanding debt was $11.5 million after considering the timing of cash settlements associated with financial transactions completed after September 30, 2024.
• The company is pursuing a CE Mark for LungFit PH in Europe, expected before year-end 2024.
• A transport-ready PMA supplement submission to the FDA for LungFit PH is anticipated in CY 1Q 2025.
• The company is conducting a Phase 1a trial for its ultra-high concentration Nitric Oxide (UNO) therapy for solid tumors, with promising preclinical data.
• A Phase 1b trial is planned for UNO + anti-PD-1 combination therapy, pending regulatory clearance in Israel.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with strong revenue growth, successful fundraising, and strategic partnerships. However, the company is still operating at a loss and has significant debt, which tempers the overall sentiment.

Positives

• The company achieved a 17% increase in revenue compared to the previous quarter.
• The number of hospital contracts increased by 60% during the quarter.
• The company secured $20.6 million in funding through a private placement.
• The company retired $17.5 million in debt, improving its financial position.
• The company has extended its cash runway to June 2026.
• The company has formed strategic partnerships to expand market access.
• Preclinical data for the ultra-high concentration Nitric Oxide (UNO) therapy is promising.
• The company is progressing towards CE Mark approval in Europe for LungFit PH.

Negatives

• Cost of revenue exceeded revenue, primarily due to depreciation of LungFit devices and one-time upgrade costs.
• The company reported a net loss of $14.0 million for the quarter ended September 30, 2024.
• The company's cash burn was $11.5 million for the quarter, excluding financing and one-time items.
• The company has a significant accumulated deficit of $265.3 million.

Risks

• The company's ability to raise additional capital is a risk.
• The timing and results of future pre-clinical studies and clinical trials are uncertain.
• Regulatory authorities may not grant or may delay approval for the company's product candidates.
• The company faces competition from others using similar technology.
• The company is dependent on collaborators.
• The company's approach to developing novel drugs is unproven and may not lead to marketable products.

Future Outlook

The company expects its strengthened balance sheet, cash conservation strategy, and anticipated revenue growth to provide sufficient cash runway to support current operating plans through June 2026. The company also anticipates a decision on CE Mark for LungFit PH in Europe before year-end 2024 and a transport-ready PMA supplement submission to FDA for LungFit PH in CY 1Q 2025.

Management Comments

• Our commercial strategy continued to drive results throughout the quarter with our total number of customers increasing by over 60%, said Steve Lisi, Chairman and Chief Executive Officer of Beyond Air.
• We believe this is just the beginning of a pivotal year for our Company as we leverage our expanding network of reference customers that have implemented LungFit PH in their hospitals.
• Our executive team and board of directors have taken decisive actions this year to enhance the Company's financial health and commercial execution as we continue accelerating our revenue growth.
• We recently implemented a capital conservation strategy to preserve cash, executed a series of financial transactions that increased our capital resources and eliminated approximately $12 million in debt-related payments through mid-2026.
• We are confident that these strategic initiatives, in conjunction with projected revenue growth, will extend our cash runway to support our current operating plans through June 2026.

Industry Context

The announcement highlights Beyond Air's progress in the medical device and biopharmaceutical industry, particularly in the nitric oxide therapy space. The company's focus on expanding its customer base and securing strategic partnerships aligns with industry trends of increasing market penetration and global expansion. The development of ultra-high concentration nitric oxide therapy for solid tumors also positions the company in the growing field of cancer immunotherapy.

Comparison to Industry Standards

• The 17% revenue increase quarter-over-quarter is a positive sign, but it's important to compare this to other medical device companies in a similar stage of commercialization. Companies like Inogen (INGN) and ResMed (RMD) have established revenue streams and are benchmarks for commercial success in respiratory devices.
• The 60% increase in hospital contracts is a strong indicator of market adoption, but it needs to be sustained. Companies like Masimo (MASI) and Medtronic (MDT) have extensive hospital networks and are good comparators for market penetration.
• The $20.6 million private placement is a common funding strategy for biotech companies, but the terms and valuation should be compared to similar deals in the sector. Companies like BioMarin (BMRN) and Vertex (VRTX) are examples of companies that have successfully raised capital.
• The debt retirement and new loan agreement are positive steps for financial health, but the royalty structure of the new loan should be evaluated against industry norms. Companies like Amgen (AMGN) and Gilead (GILD) have complex financing structures that can be used as benchmarks.
• The progress in clinical trials for ultra-high concentration nitric oxide therapy is promising, but the timeline and success rate should be compared to other companies in the oncology space. Companies like Bristol Myers Squibb (BMY) and Merck (MRK) are leaders in cancer immunotherapy and are good comparators for clinical development.

Related Party Transactions

• The company entered into a $11.5 million loan agreement with an insider-led investor group.

Stakeholder Impact

• Shareholders will benefit from the increased revenue, extended cash runway, and potential for future growth.
• Employees may experience increased job security due to the improved financial position of the company.
• Customers will have access to the LungFit PH system through expanded partnerships and market access.
• Suppliers may see increased demand for their products and services.
• Creditors will benefit from the company's debt retirement and improved financial stability.

Next Steps

• The company will continue to focus on commercializing LungFit PH and expanding its customer base.
• The company will pursue a CE Mark for LungFit PH in Europe.
• The company will submit a transport-ready PMA supplement to the FDA for LungFit PH.
• The company will continue clinical trials for its ultra-high concentration Nitric Oxide (UNO) therapy.
• The company will seek additional capital to perform human studies for the Beyond Cancer program.

Key Dates

Keywords

Nitric Oxide, LungFit PH, Medical Device, Biopharmaceutical, Private Placement, Debt Retirement, Revenue Growth, Clinical Trials, FDA Approval, CE Mark, Solid Tumors, Cancer Therapy, Healthcare, Financial Results